Straits Times Index
3,332.80 -10.55 (-0.32%) S&P 500
5,460.48 -22.39 (-0.41%) Dow
39,118.86 -45.24 (-0.12%) Nasdaq
17,732.60 -126.10 (-0.71%) Bitcoin USD
61,979.71 +1,021.41 (+1.68%) CMC Crypto 200
1,287.17 +3.34 (+0.26%)
ALLO Jul 2024 2.500 call
- Simply Wall St.
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Allogene Therapeutics' stock price is sensitive to...
- Insider Monkey
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against the other small-cap stocks. Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion. They are usually […]
- GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Ex
